SAFETY DATA SHEET

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Trade name or designation of the mixture	ADVAIR DISKUS
Registration number	-
Synonyms	ADVAIR DISKUS 50/100 MCG * ADVAIR DISKUS 50/250 MCG * ADVAIR DISKUS 50/500 MCG * SERETIDE ACCUHALER 100, 60 DOSE * SERETIDE ACCUHALER 250, 60 DOSE * SERETIDE ACCUHALER 500, 60 DOSE * SERETIDE DISKUS * SERETAIDE DISKUS * VIANI MITE 50 MCG/100 MCG DISKUS * VIANI 50 MCG/250 MCG DISKUS * VIANI FORTE 50 MCG/500 MCG DISKUS * SALMETEROL XINAFOATE (SALMETEROL HYDROXYNAPHTHOATE) AND FLUTICASONE PROPIONATE, FORMULATED PRODUCT
Issue date	03-December-2013
Version number	18
Revision date	03-December-2013
Supersedes date	03-December-2013

1.2. Relevant identified uses of the substance or mixture and uses advised against

Identified uses	Medicinal Product This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.
Uses advised against	No other uses are advised.

1.3. Details of the supplier of the safety data sheet

GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000
Email Address: msds@gsk.com
Website: www.gsk.com

1.4. Emergency telephone number

TRANSPORT EMERGENCIES::
UK In-country toll call: +(44)-870-8200418
International toll call: +1 703 527 3887
available 24 hrs/7 days; multi-language response

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to Directive 67/548/EEC or 1999/45/EC as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Classification according to Regulation (EC) No 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

2.2. Label elements

Label according to Regulation (EC) No. 1272/2008 as amended

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Supplemental label information 97.6 % of the mixture consists of component(s) of unknown acute oral toxicity.

2.3. Other hazards Assume that this product is capable of sustaining combustion.
Caution - Pharmaceutical agent. See section 11 for additional information on health hazards.

SECTION 3: Composition/information on ingredients

3.2. Mixtures

General information

Chemical name	%	CAS-No. / EC No.	REACH Registration No.	INDEX No.	Notes
FLUTICASONE PROPIONATE	0.8 - 4.0	80474-14-2 -	-	-	
Classification:	**DSD:** Repr. Cat. 2;R61, Repr. Cat. 3;R62, Xn;R48/20/21, R53				
	CLP: Repr. 1B;H360D, Repr. 2;H361f, STOT RE 2;H373				
SALMETEROL XINAFOATE	0.6	94749-08-3 -	-	-	
Classification:	**DSD:** Xi;R36/38, N;R51/53				
	CLP: Skin Irrit. 2;H315, Eye Irrit. 2;H319				
Other components below reportable levels	>95.0				

CLP: Regulation No. 1272/2008.
DSD: Directive 67/548/EEC.
M: M-factor
vPvB: very persistent and very bioaccumulative substance.
PBT: persistent, bioaccumulative and toxic substance.
#: This substance has been assigned Community workplace exposure limit(s).

Composition comments The full text for all R- and H-phrases is displayed in section 16.

SECTION 4: First aid measures

General information If you feel unwell, seek medical advice (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

4.1. Description of first aid measures

Inhalation If dust from the material is inhaled, remove the affected person immediately to fresh air.

Skin contact Wash off with soap and water. Get medical attention if irritation develops and persists.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion Rinse mouth. Get medical attention if symptoms occur.

4.2. Most important symptoms and effects, both acute and delayed The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; headache; inflamed nasal cavity; back pain; joint pain; coughing; nausea; vomiting.

4.3. Indication of any immediate medical attention and special treatment needed Provide general supportive measures and treat symptomatically.

SECTION 5: Firefighting measures

General fire hazards Assume that this product is capable of sustaining combustion.

5.1. Extinguishing media

Suitable extinguishing media Water. Foam. Dry chemical powder.

Unsuitable extinguishing media Carbon dioxide (CO_2).

5.2. Special hazards arising from the substance or mixture During fire, gases hazardous to health may be formed.

5.3. Advice for firefighters

Special protective equipment for firefighters Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Special fire fighting procedures Use standard firefighting procedures and consider the hazards of other involved materials. In the event of fire, cool tanks with water spray. Move containers from fire area if you can do so without risk.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

For non-emergency personnel Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Wear appropriate personal protective equipment. Wear a dust mask if dust is generated above exposure limits. Avoid inhalation of dust from the spilled material. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be contained. For personal protection, see section 8.

For emergency responders Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the MSDS.

6.2. Environmental precautions Avoid release to the environment. Contact local authorities in case of spillage to drain/aquatic environment. Prevent further leakage or spillage if safe to do so. Do not contaminate water. Avoid discharge into drains, water courses or onto the ground.

6.3. Methods and material for containment and cleaning up Minimise dust generation and accumulation. Collect spillage. If sweeping of a contaminated area is necessary use a dust suppressant agent which does not react with the product. Sweep up or vacuum up spillage and collect in suitable container for disposal. Collect dust using a vacuum cleaner equipped with HEPA filter. Prevent product from entering drains. Following product recovery, flush area with water.

6.4. Reference to other sections For personal protection, see section 8. For waste disposal, see section 13.

SECTION 7: Handling and storage

7.1. Precautions for safe handling Minimise dust generation and accumulation. Provide appropriate exhaust ventilation at places where dust is formed. Avoid breathing dust. Avoid contact with skin and eyes. Wear appropriate personal protective equipment. Observe good industrial hygiene practices. Practice good housekeeping. Avoid release to the environment. Do not empty into drains.

7.2. Conditions for safe storage, including any incompatibilities Keep away from heat and sources of ignition. Store in original tightly closed container. Store in a cool, dry place out of direct sunlight. Store in a well-ventilated place. Guard against dust accumulation of this material. Store away from incompatible materials (see Section 10 of the MSDS).

7.3. Specific end use(s) Medicinal Product

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Occupational exposure limits

GSK

Components	Type	Value	Note
FLUTICASONE PROPIONATE (CAS 80474-14-2)	8 HR TWA	3 mcg/m3	
	OHC	4	Skin
		4	Reproductive hazard
SALMETEROL XINAFOATE (CAS 94749-08-3)	8 HR TWA	1 mcg/m3	
	OHC	5	

Biological limit values No biological exposure limits noted for the ingredient(s).

Recommended monitoring procedures Follow standard monitoring procedures.

Derived No Effect Level (DNEL) Not available.

Predicted no effect concentrations (PNECs) Not available.

8.2. Exposure controls

Appropriate engineering controls An Exposure Control Approach (ECA) is established for operations involving this material based upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. Good general ventilation (typically 10 air changes per hour) should be used. Ventilation rates should be matched to conditions. If applicable, use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels to an acceptable level.

Individual protection measures, such as personal protective equipment

General information Personal protection equipment should be chosen according to the CEN standards and in discussion with the supplier of the personal protective equipment. Follow all local regulations if personal protective equipment (PPE) is used in the workplace.

Eye/face protection Use tight fitting goggles if dust is generated. (eg. EN 166)

Skin protection

- Hand protection The choice of an appropriate glove does not only depend on its material but also on other quality features and is different from one producer to the other. Glove selection must take into account any solvents and other hazards present. With respect to the above precautions select suitable chemical resistant protective gloves (EN 374) with a protective index 6 (>480min permeation time).

- Other Wear suitable protective clothing. (EN 14605 for splashes, EN ISO 13982 for dust)

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate certified respirators. Where breathable aerosols/dust are formed, use suitable combination filter for gases/vapours of organic, inorganic, acid inorganic, alkaline compounds and toxic particles (eg. EN 14387).

Thermal hazards	Wear appropriate thermal protective clothing, when necessary.
Hygiene measures	Always observe good personal hygiene measures, such as washing after handling the material and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants.

Environmental exposure controls

Hazard guidance and control recommendations	Contain spills and prevent releases and observe national regulations on emissions. Environmental manager must be informed of all major releases.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Appearance

Physical state	Solid.
Form	Powder.
Colour	White.
Odour	Not available.
Odour threshold	Not available.
pH	Not available.
Melting point/freezing point	Not available.
Initial boiling point and boiling range	Not available.
Flash point	Not available.
Evaporation rate	Not available.
Flammability (solid, gas)	Not available.

Upper/lower flammability or explosive limits

Flammability limit - lower (%)	Not available.
Flammability limit - upper (%)	Not available.
Vapour pressure	Not available.
Vapour density	Not available.
Relative density	Not available.
Solubility(ies)	Not available.
Partition coefficient (n-octanol/water)	Not available.
Auto-ignition temperature	Not available.
Decomposition temperature	Not available.
Viscosity	Not available.
Explosive properties	Not available.
Oxidizing properties	Not available.
9.2. Other information	No relevant additional information available.

SECTION 10: Stability and reactivity

10.1. Reactivity	The product is stable and non-reactive under normal conditions of use, storage and transport.
10.2. Chemical stability	Material is stable under normal conditions.
10.3. Possibility of hazardous reactions	No dangerous reaction known under conditions of normal use.
10.4. Conditions to avoid	Avoid heat, sparks, open flames and other ignition sources. Contact with incompatible materials.
10.5. Incompatible materials	Strong oxidising agents.
10.6. Hazardous decomposition products	Irritating and/or toxic fumes and gases may be emitted upon the products decomposition.

SECTION 11: Toxicological information

General information	Caution - Pharmaceutical agent.

Information on likely routes of exposure

Ingestion	Health injuries are not known or expected under normal use.

Inhalation	Health injuries are not known or expected under normal use. Inhalation of dusts may cause respiratory irritation.
Skin contact	Health injuries are not known or expected under normal use.
Eye contact	Dust in the eyes will cause irritation. Health injuries are not known or expected under normal use.
Symptoms	The following adverse effects have been noted with therapeutic use of this material: increased susceptibility to infection; headache; inflamed nasal cavity; back pain; joint pain; coughing; nausea; vomiting.

11.1. Information on toxicological effects

Acute toxicity Health injuries are not known or expected under normal use.

Components	Species	Test results
FLUTICASONE PROPIONATE (CAS 80474-14-2)		
Acute		
Oral		
LD50	Rat	> 1000 mg/kg
Subacute		
Inhalation		
NOAEL	Rat	0.2 mcg/L/day, 28 Day
Subchronic		
Inhalation		
LOEL	Rat	3 mcg/kg/day, 26 weeks
NOAEL	Dog	68 mcg/kg/day, 26 weeks
	Rat	14 mcg/kg/day, 26 weeks
SALMETEROL XINAFOATE (CAS 94749-08-3)		
Acute		
Inhalation		
LC50	Rat	> 75 mg/l
Oral		
LD50	Rat	> 1000 mg/kg
Subchronic		
Inhalation		
LOEL	Rat	>= 0.16 mg/kg/day, 26 weeks, adrenergic effects
Oral		
NOAEL	Rat	0.2 mg/kg/day, 26 weeks, adrenergic effects

* Estimates for product may be based on additional component data not shown.

Skin corrosion/irritation Health injuries are not known or expected under normal use. Due to partial or complete lack of data the classification is not possible.

Corrosivity

FLUTICASONE PROPIONATE	OECD 404 Result: negative
SALMETEROL XINAFOATE	Result: Irritant Species: Human

Irritation Corrosion - Skin: P.I.I. value

FLUTICASONE PROPIONATE	0

Serious eye damage/eye irritation Dust in the eyes will cause irritation.

Eye

SALMETEROL XINAFOATE	OECD 405 Result: Severe Species: Rabbit
FLUTICASONE PROPIONATE	OECD 405 Result: negative Species: Rabbit

Respiratory sensitisation Due to partial or complete lack of data the classification is not possible.

Skin sensitisation Due to partial or complete lack of data the classification is not possible.

Maximisation assay (Magnusson and Kligman)

SALMETEROL XINAFOATE	Result: negative Species: Guinea pig

Sensitisation

FLUTICASONE PROPIONATE	0 % OECD 406 Result: negative Species: Guinea pig

Germ cell mutagenicity Due to partial or complete lack of data the classification is not possible.

Germ cell mutagenicity

Mutagenicity

FLUTICASONE PROPIONATE	Ames Result: negative
SALMETEROL XINAFOATE	Ames - Screen Result: negative
FLUTICASONE PROPIONATE	Bacterial High Throughput Fluctuation Test Result: negative Chinese Hamster Ovarian Cell Test Result: negative
SALMETEROL XINAFOATE	Chromosomal aberration assay Result: negative GreenScreen Assay Result: negative HPRT gene mutation in human lymphocytes Result: negative High throughput fluctuation test (HTFT) Result: negative In vitro cytogenetic Assay Result: negative L5178Y mouse lymphoma thymidine kinase locus assay Result: negative
FLUTICASONE PROPIONATE	Micronucleus Assay Result: negative Species: Mouse Micronucleus Test Result: negative Species: Mouse
SALMETEROL XINAFOATE	Rat Micronucleus Assay Result: negative
FLUTICASONE PROPIONATE	SOS/umu Assay Result: negative Yeast Result: negative

Carcinogenicity This product is not considered to be a carcinogen by IARC, ACGIH, NTP, or OSHA. Not classifiable as to carcinogenicity to humans.

SALMETEROL XINAFOATE	>= 0.15 mg/kg/day, Species-specific Result: positive Species: Rat Organ: Pituitary/ Uterus >= 1.4 mg/kg/day, Species-specific Result: positive Species: Mouse Organ: uterus
FLUTICASONE PROPIONATE	Inhalation Result: negative Species: Rat dermal Result: negative Species: Mouse oral Result: negative Species: Mouse

Reproductive toxicity Components in this product have been shown to cause birth defects and reproductive disorders in laboratory animals.

Reproductive toxicity

Reproductivity

SALMETEROL XINAFOATE	0.1 mg/kg/day Reproductive performance and development of two untreated generations, NOEL Species: Rat Notes: GR33343X 1 mg/kg/day Reproductive performance and development of two untreated generations Species: Rat Organ: Skeletal effects Notes: GR33343X

Reproductivity

FLUTICASONE PROPIONATE	100 mcg/kg/day Embryofetal Development Result: reduced foetal bodyweight, minor skeletal variations Species: Rat 100 mcg/kg/day Female fertility (Segment I) Result: reduced foetal bodyweight, minor skeletal variations Species: Rat
SALMETEROL XINAFOATE	2 mg/kg/day Reproductive performance and development of two untreated generations, NOAEL Species: Rat Notes: GR33343G
FLUTICASONE PROPIONATE	50 mcg/kg/day Pre- and Post-natal development Result: maternal toxicity Species: Rat
SALMETEROL XINAFOATE	>= 1 mg/kg/day Embryo-foetal development- Oral, Species-specific Species: Rabbit Organ: Skeletal effects, open eye, cleft palate Notes: GR33343G
FLUTICASONE PROPIONATE	>= 25.7 mcg/kg/day Embryofetal Development Result: maternal toxicity, reduced foetal body weight; no malformations or other variations Species: Rat >= 45 mcg/kg/day Embryofetal Development Result: cleft palate Species: Mouse >= 50 mcg/kg/day Embryofetal Development Result: maternal toxicity; reduced foetal weight; foetal resorptions Species: Rabbit SAR / QSAR, Glucocorticoid

Specific target organ toxicity - single exposure Heart.

Specific target organ toxicity - repeated exposure May cause damage to organs through prolonged or repeated exposure. Adrenal glands. Bone tissue. Immune system.

Aspiration hazard Due to partial or complete lack of data the classification is not possible.

Mixture versus substance information No information available.

Other information Caution - Pharmaceutical agent.

SECTION 12: Ecological information

12.1. Toxicity No information is available about the potential of this product to produce adverse environmental effects. The product contains a substance which may cause long-term adverse effects in the environment.

Components		Species	Test results
FLUTICASONE PROPIONATE (CAS 80474-14-2)			
Acute			
	IC50	Activated sludge	> 1000 mg/l, 3 hours
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	> 0.55 mg/l, 48 hours, Static test
Terrestrial			
Acute			
Earthworm	EC50	Manure worm (Eisenia foetida)	> 1000 mg/kg, 28 days
SALMETEROL XINAFOATE (CAS 94749-08-3)			
Aquatic			
Acute			
Activated Sludge Respiration	IC50	Residential sludge	> 998 mg/l, 3 hours, OECD 209
Algae	EC50	Green algae (Scenedesmus subspicatus)	4 mg/l, 72 hours, Measured, OECD 201
	NOEC	Green algae (Scenedesmus subspicatus)	1.9 mg/l

Components		Species	Test results
Crustacea	EC50	Water flea (Daphnia pulex)	20 mg/l, 48 hours, OECD 202
	NOEC	Water flea (Daphnia pulex)	6.7 mg/l, 48 hours
Fish	EC50	Rainbow trout (Juvenile Oncorhyncus mykiss)	35 mg/l, 96 hours, Static renewal test, OECD 203
	NOEC	Rainbow trout (Juvenile Oncorhyncus mykiss)	7.5 mg/l
Chronic			
Crustacea	LOEC	Water flea (Ceriodaphnia dubia)	5 mg/l, 8 days, Static renewal test, EPA Method 1002
	NOEC	Water flea (Ceriodaphnia dubia)	1.6 mg/l, 8 days
Terrestrial			
Acute			
Earthworm	EC50	Manure worm (Eisenia foetida)	334 mg/kg, 28 days, OECD 222
	NOEC	Manure worm (Eisenia foetida)	209 mg/kg, 28 days

* Estimates for product may be based on additional component data not shown.

12.2. Persistence and degradability

Persistence and degradability

Photolysis

UV/visible spectrum wavelength

SALMETEROL XINAFOATE	338 nm

Hydrolysis

Half-life (Hydrolysis-neutral)

FLUTICASONE PROPIONATE	> 1 years Measured
SALMETEROL XINAFOATE	> 1 years Measured

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

SALMETEROL XINAFOATE	50 %, 12.8 days Modified Zahn-Wellens, primary biodegradation, loss of parent.

Percent degradation (Aerobic biodegradation-ready)

FLUTICASONE PROPIONATE	< 44 %, 28 days

Percent degradation (Aerobic biodegradation-soil)

FLUTICASONE PROPIONATE	9 - 50 %, 64 days
SALMETEROL XINAFOATE	29.9 - 49.9 %, 64 days

12.3. Bioaccumulative potential

Partition coefficient n-octanol/water (log Kow)

FLUTICASONE PROPIONATE	2.78
SALMETEROL XINAFOATE	2.1 (Measured).

12.4. Mobility in soil

Adsorption

Sludge/biomass distribution coefficient - log Kd

FLUTICASONE PROPIONATE	3.13 - 3.55 Estimated

Soil/sediment sorption - log Koc

FLUTICASONE PROPIONATE	3.41 - 3.83 Measured
SALMETEROL XINAFOATE	3.84 - 4.52

Mobility in general

Distribution

Octanol/water distribution coefficient log DOW

SALMETEROL XINAFOATE	1.32, pH 9 1.71, pH 7 2.06, pH 5

12.5. Results of PBT and vPvB assessment Not available.

12.6. Other adverse effects Not available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Residual waste	Dispose of in accordance with local regulations. Empty containers or liners may retain some product residues. This material and its container must be disposed of in a safe manner (see: Disposal instructions).
Contaminated packaging	Empty containers should be taken to an approved waste handling site for recycling or disposal. Since emptied containers may retain product residue, follow label warnings even after container is emptied.
EU waste code	The Waste code should be assigned in discussion between the user, the producer and the waste disposal company.
Disposal methods/information	Collect and reclaim or dispose in sealed containers at licensed waste disposal site. This material and its container must be disposed of as hazardous waste. Do not allow this material to drain into sewers/water supplies. Do not contaminate ponds, waterways or ditches with chemical or used container. Dispose of contents/container in accordance with local/regional/national/international regulations.
Special precautions	Dispose in accordance with all applicable regulations.

SECTION 14: Transport information

ADR

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

14.7. Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	MARPOL Annex II applies to liquids used in a ship's operation that pose a threat to the marine environment. These materials may not be transported in bulk.

SECTION 15: Regulatory information

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

EU regulations

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex I

Not listed.

Regulation (EC) No. 1005/2009 on substances that deplete the ozone layer, Annex II

Not listed.

Regulation (EC) No. 850/2004 On persistent organic pollutants, Annex I as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 1 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 2 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex I, part 3 as amended

Not listed.

Regulation (EC) No. 689/2008 concerning the export and import of dangerous chemicals, Annex V as amended

Not listed.

Regulation (EC) No. 166/2006 Annex II Pollutant Release and Transfer Registry

Not listed.

Regulation (EC) No. 1907/2006, REACH Article 59(1) Candidate List as currently published by ECHA

Not listed.

Authorisations

Regulation (EC) No. 1907/2006, REACH Annex XIV Substances subject to authorization, as amended

Not listed.

Restrictions on use

Regulation (EC) No. 1907/2006, REACH Annex XVII Substances subject to restriction on marketing and use as amended

Not listed.

Directive 2004/37/EC: on the protection of workers from the risks related to exposure to carcinogens and mutagens at work

Not listed.

Directive 92/85/EEC: on the safety and health of pregnant workers and workers who have recently given birth or are breastfeeding

Not listed.

Other EU regulations

Directive 96/82/EC (Seveso II) on the control of major-accident hazards involving dangerous substances

Not listed.

Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work

Not listed.

Directive 94/33/EC on the protection of young people at work

Not listed.

Other regulations	The product is classified and labelled in accordance with EC directives or respective national laws. This Safety Data Sheet complies with the requirements of Regulation (EC) No 1907/2006.
National regulations	Follow national regulation for work with chemical agents.
15.2. Chemical safety assessment	No Chemical Safety Assessment has been carried out.

SECTION 16: Other information

List of abbreviations	Not available.
References	GSK Hazard Determination
Information on evaluation method leading to the classification of mixture	The classification for health and environmental hazards is derived by a combination of calculation methods and test data, if available.
Full text of any statements or R-phrases and H-statements under Sections 2 to 15	R36/38 Irritating to eyes and skin. R48/20/21 Harmful: danger of serious damage to health by prolonged exposure through inhalation and in contact with skin. R51/53 Toxic to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R52/53 Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment. R53 May cause long term adverse effects in the aquatic environment. R61 May cause harm to the unborn child. R62 Possible risk of impaired fertility. H315 Causes skin irritation. H319 Causes serious eye irritation. H360D May damage the unborn child. H361f Suspected of damaging fertility.
Revision information	Product and Company Identification: Business Units Composition / Information on Ingredients: Ingredients Physical & Chemical Properties: Reports Ecological Information: Reports Transport Information: Agency Name and Packaging Type/Transport Mode Selection Regulatory Information: United States
Training information	Follow training instructions when handling this material.
Disclaimer	The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.